Biotech company Moderna announced the final results of the 30,000-person efficacy trial for its candidate vaccine: Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic Coronavirus, versus 185 symptomatic cases in a placebo group. That is an efficacy of 94.1%, the company says.
Moderna also says that its candidate vaccine had 100% efficacy against Severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 such cases in the placebo group.
Moderna plans to file a request for emergency use authorization (EUA) for its vaccine with the U.S. Food and Drug Administration (FDA), and is also seeking a similar green light from the European Medicines Agency.
“This is excellent news”, explains Dr. Yael Vidal of Vidal Medical Concierge, a private practice of Concierge Medicine located in Juno Beach , Florida and serving the nearby areas. “We are thrilled to learn about this positive development, which may greatly assist in fighting this pandemic.”